Get started
Author

Birgit C. Schultes

Observed names: B Schultes, B. C. Schultes, B. Schultes, B. Shultes, B.C. SCHULTES, B.C. Schultes, BIRGIT C. SCHULTES, BIRGIT SCHULTES, Birgit C Schultes, Birgit C. SCHULTES, Birgit Corinna SCHULTES, Birgit Corinna Schultes, Birgit Schultes, Schultes, Birgit
Observed institutions: University of Bonn, University of Alberta, University of California, Los Angeles, University of Pittsburgh, Universität Ulm, SUNY Upstate Medical University, MedStar Franklin Square Medical Center, University Hospital Bonn, Florida Hospital Cancer Institute, Swedish Medical Center, Momenta Pharmaceuticals (United States), Advanced Immune Therapeutics (United States), Intellia Therapeutics (United States), Stanford Medicine, University of Virginia Cancer Center, Veristat, LLC (United States), University of Virginia, Stanford University
ORCID: 0000-0002-2275-3383
Observed ORCID: 0000-0002-2275-3383
OpenAlex ID: A5050867417
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity
2015 · Nathaniel Washburn, Inessa Schwab, et al. · Proceedings of the National Academy of Sciences · 227
Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer
2004 · Jonathan S. Berek, Peyton T. Taylor, et al. · Journal of Clinical Oncology · 192
PDF
M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis
2011 · He Zhou, Sucharita Roy, et al. · PLoS ONE · 183
PDF
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
2008 · Jonathan Berek, Peyton Taylor, et al. · Journal of Clinical Oncology · 173
Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo
2001 · Antoine A. Noujaim, Birgit C. Schultes, et al. · Cancer Biotherapy and Radiopharmaceuticals · 109
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients
2004 · Alan N Gordon, Birgit C Schultes, et al. · Gynecologic Oncology · 87
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab 3 ) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab 1 )
1998 · Birgit C. Schultes, Richard P. Baum, et al. · Cancer Immunology Immunotherapy · 87
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
2005 · T.G. EHLEN, P.J. HOSKINS, et al. · International Journal of Gynecological Cancer · 83
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
2004 · J.S. de Bono, S.Y. Rha, et al. · Annals of Oncology · 73
PDF
Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors
2016 · Daniel F. Ortiz, Jonathan C. Lansing, et al. · Science Translational Medicine · 72
Generation of CD4+ and CD8+ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes
2001 · Kathleen A. Berlyn, Birgit Schultes, et al. · Clinical Immunology · 66
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer
2003 · Volker J. Möbus, Richard P. Baum, et al. · American Journal of Obstetrics and Gynecology · 63
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
2022 · Eliana Ruggiero, Erica Carnevale, et al. · Science Translational Medicine · 58
PDF
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
2013 · Tracy R Daniels-Wells, Gustavo Helguera, et al. · BMC Cancer · 57
PDF
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells
2011 · Tracy R. Daniels, Richard K. Leuchter, et al. · Cancer Immunology Immunotherapy · 46
PDF
Synthesis and Biological Evaluation of a Unique Heparin Mimetic Hexasaccharide for Structure–Activity Relationship Studies
2014 · Sucharita Roy, Ahmed El Hadri, et al. · Journal of Medicinal Chemistry · 44
Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay
2003 · Birgit C. Schultes, Theresa L. Whiteside · Journal of Immunological Methods · 34
Immunotherapy of Human Ovarian Carcinoma with OVAREX TM MAb-B43.13 in a Human-PBL-SCID/BG Mouse Model
1999 · BIRGIT C. SCHULTES, CHENGSHENG ZHANG, et al. · Hybridoma · 33
A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer
1995 · HARALD SCHLEBUSCH, UWE WAGNER, et al. · Hybridoma · 33
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors
2017 · Kamiya Mehla, Jarrod Tremayne, et al. · Cancer Immunology Immunotherapy · 28
Characterization of an Anti-MUC1 Monoclonal Antibody with Potential as a Cancer Vaccine
2001 · Weimin Qi, Birgit C. Schultes, et al. · Hybridoma and Hybridomics · 25
Expression of a fusion protein of scFv–biotin mimetic peptide for immunoassay
1998 · D Luo, M Geng, et al. · Journal of Biotechnology · 25
Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
2018 · Amanda MacDonald, Michelle Priess, et al. · Molecular Cancer Therapeutics · 23
Summary Report on the ISOBM TD-6 Workshop: Analysis of 20 Monoclonal Antibodies against Sialyl Lewisa and Related Antigens
1998 · P.D. Rye, N.V. Bovin, et al. · Tumor Biology · 21
Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab')2 fragments of OC125 antibody
1993 · J Reinsberg, B Schultes, et al. · Clinical Chemistry · 20
Works count: 98
Citation count: 2,061
H-index: 23
I10-index: 35
Year
Topic
Type